Novel Therapeutics in Development for CSU

Author(s):

Key Takeaways

Steroids offer rapid symptom relief in CSU but are generally reserved for short-term use due to adverse effects.
Long-term systemic steroid use can lead to significant side effects, including osteoporosis, hypertension, and glucose intolerance.
Practitioners must weigh the benefits of symptom control against potential harm and consider alternative long-term management strategies.

Panelists discuss how the integration of advanced treatments such as biologics and Bruton tyrosine kinase (BTK) inhibitors can bridge the gap in managing chronic spontaneous urticaria (CSU) for patients unresponsive to antihistamines.

EP: 1.Bringing CSU Back Under The House of Dermatology

EP: 2.Understanding the Chronicity of CSU

EP: 3.The Psychosocial Impact of CSU

EP: 4.The Pathogenesis of CSU

EP: 5.Tips on Diagnosing CSU

EP: 6.Less Is More: Diagnostic Testing for CSU

EP: 7.Disease Severity and Delays in Treatment in CSU

EP: 8.The Role of Dermatologists in Treating CSU

EP: 9.Treatment Approaches and the Limitations of Antihistamines for CSU

EP: 10.Steroids and Immunosuppressive Agents for CSU

Now Viewing

EP: 11.Novel Therapeutics in Development for CSU

EP: 12.The Role of BTK Inhibition in CSU

EP: 13.The Importance of Patient Education and Shared Decision-Making in CSU

EP: 14.The Role of BTK Inhibitors in the Evolving CSU Treatment Landscape

Video content above is prompted by the following:

Can you describe what you see as the current and future role of advanced treatments such as biologics and BTK inhibitors in CSU management?
1. What gap currently exists in transitioning from antihistamine cycling to a biologic?